The New York Times (9/29, Swift, Goodnough) reports since the COVID-19 pandemic began, opioid-related deaths have increased in more than 40 states. The pandemic disrupted daily life for many in recovery by reducing access to treatment, disrupting employment, and isolating people from those they depend on for support.

Related Links:

— “‘The Drug Became His Friend”: Pandemic Drives Hike in Opiods Deaths ” Hilary Swift and Abby Goodnough, The New York Times, September 29, 2020

CNN (9/29, Mascarenhas) reports researchers at the RAND Corporation found “Americans over 30 have been drinking more during the coronavirus pandemic compared to this time last year, and there could be consequences to their physical and mental health.” The findings were published in JAMA Network Open.

TIME (9/29, Kluger) reports that “during the week ending March 21, national alcohol sales increased 54% from the same week a year before and online sales leapt a staggering 262%.” The researchers also found that “adults reported drinking 14% more than they did the year before.”

Other sources covering the story include: HealthDay (9/29, Mozes), MedPage Today (9/29, Walker), and Medscape (9/29, Brooks, Subscription Publication).

Related Links:

— “Americans over 30 have been drinking more during the coronavirus pandemic, research shows ” Lauren Mascarenhas, CNN, September 29, 2020

Psychiatric News (9/29) reports that while “specialty team-based services for first-episode psychosis (FEP) have the potential to improve outcomes among patients with schizophrenia,” in a viewpoint article, psychiatrists Maria Ferrara, MD, and Vinod H. Srihari, MD, of Yale University “described several factors that may disadvantage women in terms of both access to and quality of care in FEP services.” Those factors include “age of onset,” “clinical presentation,” “pathways to care,” “sexual and reproductive health,” and “preventive medicine.” The viewpoint was published online Sept. 23 in Psychiatric Services, a publication of the American Psychiatric Association.

Related Links:

— “Women With First-Episode Psychosis Not Getting Targeted Care They Need Psychiatric News, September 29, 2020

The AP (9/28, Morgan) reports, “While suicide has long been a problem in the U.S. military, numbers have risen this year by as much as 20% as service members struggle with isolation and other impacts of COVID-19, added to the pressures of deploying to war zones and responding to national disasters and civil unrest.” Due to the COVID-19 pandemic, soldiers returning home earlier this year were restricted from visiting families and friends out-of-state and “patriotic welcome home ceremonies were replaced with a mandatory two-week quarantine.” The AP adds that the US Army is considering different measures, such as shortening deployment periods, to improve well-being and reduce suicides.

Related Links:

— “As suicides rise, Army brass reassessing outreach “Sarah Blake Morgan, AP, September 28, 2020

Healio (9/28, Miller) cites researchers in reporting that “the FDA has often approved new drug applications for opioids based on trials of inadequate length that included only patients who could tolerate the drugs.” The researchers “examined 48 new drug applications (NDAs) that were approved by the FDA between 1997 and 2018.” The trials that supported the applications “lasted a median of 84 days” though according to one researcher, many patients would take these medications for longer than that. The findings were published in Annals of Internal Medicine.

Related Links:

— “FDA approved opioids based on limited data, sometimes ‘flawed’ trial designs “Janel Miller, Healio, September 28, 2020